Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
76.86 CHF | -1.00% |
|
-0.77% | -.--% |
06-24 | Foreign banks target Switzerland after UBS takeover of Credit Suisse | RE |
06-24 | NOVARTIS AG : Barclays reaffirms its Sell rating | ZD |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 219B | - | ||
+55.08% | 815B | C+ | ||
+45.31% | 654B | B | ||
-6.70% | 354B | C+ | ||
+21.56% | 337B | B- | ||
+9.94% | 302B | C+ | ||
+17.70% | 247B | B+ | ||
+2.04% | 229B | A+ | ||
+9.58% | 171B | C+ | ||
-3.54% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- 0QM7 Stock
- Ratings Novartis AG